7
ALL7
WockhardtYear
7
ALL1
20252
20241
20221
20212
2020DEALS // DEV.
7
ALL5
Deals2
DevelopmentsCountry
7
ALL7
INDIA7
ALL1
Glenmark Pharmaceuticals1
ICICI Prudential1
Inapplicable1
Jiangxi Jemincare Group Company1
Not Applicable1
U.S Government1
UK GovernmentTherapeutic Area
7
ALL1
Gastroenterology6
Infections and Infectious DiseasesStudy Phase
7
ALL1
Approved FDF1
Approved4
Phase III1
Phase IIDeal Type
6
ALL1
Acquisition2
Agreement1
Inapplicable1
Partnership1
Private PlacementProduct Type
7
ALL1
Antibiotic4
Small molecule2
VaccineDosage Form
6
ALL1
Infusion2
Intramuscular Injection1
Oral2
TabletLead Product
7
ALL1
Cefepime2
ChAdOx1 nCoV-191
Famotidine3
NafithromycinTarget
2
ALL1
Bacterial 70S ribosome1
H2 receptorLead Product(s) : Nafithromycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CDSCO Approves Wockhardt’s New Generation Oral Antibiotic Miqnaf
Details : Miqnaf (nafithromycin) is a novel antibiotic discovered and being developed for the treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults.
Product Name : Miqnaf
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 03, 2025
Lead Product(s) : Nafithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nafithromycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Indian Drug Regulator Recommends Wockhardt's Miqnaf for Treatment of CABP
Details : Miqnaf (nafithromycin) is a novel antibiotic discovered and being developed for the treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults.
Product Name : Miqnaf
Product Type : Small molecule
Upfront Cash : Not Applicable
October 14, 2024
Lead Product(s) : Nafithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cefepime,Zidebactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : ICICI Prudential
Deal Size : $57.5 million
Deal Type : Private Placement
Wockhardt Raises Rs 480 Crore to Pare Debt, Fund Drug Trial
Details : WCK 5222, a combination of cefepime and zidebactam, is in a Phase 3 trial for complicated urinary tract infections globally.
Product Name : WCK 5222
Product Type : Small molecule
Upfront Cash : Undisclosed
March 28, 2024
Lead Product(s) : Cefepime,Zidebactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : ICICI Prudential
Deal Size : $57.5 million
Deal Type : Private Placement
Lead Product(s) : Famotidine
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Glenmark has acquired the approved ANDAs for Famotidine Tablets USP, 10 mg and 20 mg, Cetirizine Hydrochloride Tablets USP, 5 mg and 10 mg, Lansoprazole DelayedRelease Capsules USP, 15 mg and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% from W...
Product Name : Famotidine- Generic
Product Type : Small molecule
Upfront Cash : Undisclosed
June 28, 2022
Lead Product(s) : Famotidine
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Nafithromycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Jiangxi Jemincare Group Company
Deal Size : Undisclosed
Deal Type : Partnership
Wockhardt and Jemincare Partner for Novel Respiratory Antibiotic Nafithromycin
Details : Under the terms of the definitive agreement, Jemincare will be responsible for exclusive development and commercialization of the Nafithromycin in the select markets.
Product Name : WCK 4873
Product Type : Small molecule
Upfront Cash : Undisclosed
August 26, 2021
Lead Product(s) : Nafithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Jiangxi Jemincare Group Company
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : ChAdOx1 nCoV-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : UK Government
Deal Size : Undisclosed
Deal Type : Agreement
Wockhardt snags Covid-19 Vaccine Manufacturing Deal From the UK Govt
Details : Wockhardt has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK Government in its fight against COVID19, including AZD1222, the vaccine co-invented by the University of Oxford and its spinout company, Vaccitech and l...
Product Name : AZD1222
Product Type : Vaccine
Upfront Cash : Undisclosed
August 03, 2020
Lead Product(s) : ChAdOx1 nCoV-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : UK Government
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : ChAdOx1 nCoV-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : U.S Government
Deal Size : Undisclosed
Deal Type : Agreement
India's Wockhardt Strikes Deal to Supply COVID-19 Vaccines to UK
Details : Wockhardt Ltd will supply millions of doses of multiple COVID-19 vaccines, including that being developed by AstraZeneca and Oxford University, under a deal with the UK government.
Product Name : AZD1222
Product Type : Vaccine
Upfront Cash : Undisclosed
August 03, 2020
Lead Product(s) : ChAdOx1 nCoV-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : U.S Government
Deal Size : Undisclosed
Deal Type : Agreement